WCN 2026 28 - 31 March 2026

Mechanistic effects of semaglutide on kidney disease in type 2 diabetes: The remodel trial

Authors :

Katherine R. Tuttle,1,2; Petter Bjornstad3,4; Menno Pruijm5; Jeffrey B. Hodgin6; David Z.I. Cherney7; Nicolas Belmar8; Milenta Mariam Chacko9; Vivek Das8; Thomas Idorn8; Philip A. Schytz8; Matthias Kretzler10

Affiliations
View Details Hide Details
{{ getPageNum(PDFPage) }}
Keywords
Chronic Kidney Disease
Congress poster
GLP-1 RA
Semaglutide
PHASE 3 (RCT)